Preliminary results of an abiraterone acetate trial

  • 12 October 2010
John Neate, Chief Executive at The Prostate Cancer Charity, spoke to the Daily Telegraph, BBC Online and The Sun about the preliminary results of a trial of almost 800 men who took abiraterone acetate and lived almost four months longer than men given a placebo. Dr Sarah Cant, Head of Policy and Campaigns at the Charity, also joined Channel 4 News to discuss the results and the need for the drug to be made widely available for the men most at need.